Is (90)Y-DOTATOC treatment for neuroendocrine tumours safe?
Cybulla
Markus
M
Department of Internal Medicine, University Hospital Freiburg, Germany. cybulla@med1.ukl.uni-freiburg.de
Weiner
Stefan M
SM
Otte
Andreas
A
D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D018276:Carcinoma, Medullary / Q000532:radiotherapy / Q000556:secondary; D006801:Humans; D006977:Hypertension, Renal / Q000139:chemically induced; D007676:Kidney Failure, Chronic / Q000139:chemically induced* / Q000517:prevention & control; D018358:Neuroendocrine Tumors / Q000532:radiotherapy*; D015282:Octreotide / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000009:adverse effects* / Q000627:therapeutic use; D017481:Receptors, Somatostatin / Q000187:drug effects; D013964:Thyroid Neoplasms / Q000473:pathology; D015021:Yttrium Radioisotopes / Q000009:adverse effects* / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; D015021:Yttrium Radioisotopes; D015282:Octreotide; C106246:Edotreotide